Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737844 | 0.95 | KIT (0.76) | KITFLT3 | |
| SCHEMBL13737976 | 0.92 | KIT (0.85) | KITFLT3 | |
| SCHEMBL13739346 | 0.89 | KIT (0.79) | KITFLT3 | |
| SCHEMBL13737900 | 0.89 | KIT (0.79) | KITFLT3 | |
| SCHEMBL13735846 | 0.87 | KIT (1.00) | KITFLT3 | |
| SCHEMBL13735916 | 0.87 | KIT (1.00) | KITFLT3 | |
| SCHEMBL13738056 | 0.86 | KIT (1.00) | KITFLT3 | |
| Hydrochloric Acid SCHEMBL13736574 | 0.85 | KIT (0.98) | KITFLT3 | |
| SCHEMBL18171381 | 0.85 | KIT (1.00) | KITFLT3 | |
| SCHEMBL18258918 | 0.85 | KIT (0.70) | KITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10478423-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-11-19 | — | — | US | disclosed |
| US-20180289672-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-10-11 | — | — | US | disclosed |
| EP-2707359-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2014-03-19 | — | — | EP | disclosed |
| WO-2012152763-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10478423-B2 | Substituted indazole derivatives active as kinase inhibitiors | MAP3K20, MAP3K1, MAP3K5 | KIT 669/4885FLT3 299/4885 |
| US-20180289672-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | KIT 669/4885FLT3 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.